Improving DxMultiomics, Powered by Your Choices

We're building DxMultiomics to be The Central Nexus of Biotech Intelligence. To ensure a seamless experience and continuous improvement, we utilize website analytics. These tools help us monitor site performance, understand how users navigate the platform, and identify opportunities to make your research journey more efficient. We handle this data with the utmost respect for your privacy, and you can choose what works best for you.

Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement
_↗ ir.mazetx.com
News Image

A clinical-stage biopharmaceutical company focused on developing precision medicines for kidney and metabolic diseases, Maze Therapeutics announced that it has secured an oversubscribed private placement of its securities, raising approximately $150.0 million in gross proceeds. The funding round saw participation from a mix of new and existing investors, including Frazier Life Sciences, Deep Track Capital, and Janus Henderson Investors, among others. The company will issue a combination of 4,000,002 shares of common stock at $16.25 per share and 5,231,090 pre-funded warrants at a slightly lower price of $16.249. These pre-funded warrants are immediately exercisable and do not expire. The transaction is expected to finalize on September 12, 2025, subject to standard closing conditions. announced that it has secured an oversubscribed private placement of its securities, raising approximately $150.0 million in gross proceeds. The funding round saw participation from a mix of new and existing investors, including Frazier Life Sciences, Deep Track Capital, and Janus Henderson Investors, among others. The company will issue a combination of 4,000,002 shares of common stock at $16.25 per share and 5,231,090 pre-funded warrants at a slightly lower price of $16.249. These pre-funded warrants are immediately exercisable and do not expire. The transaction is expected to finalize on September 12, 2025, subject to standard closing conditions.

Maze Therapeutics plans to use the capital from this private placement, combined with its existing financial resources, to advance several key initiatives. The proceeds will be used to further the development of MZE829, a treatment for APOL1-mediated kidney disease, and to begin Phase 2 clinical trials for MZE782 in patients with both phenylketonuria (PKU) and chronic kidney disease (CKD). Additionally, the funds will support the company's research and discovery programs, aid in the continued development of its Compass™ platform, and be used for general corporate purposes and working capital. The company noted that the securities sold in this private placement have not been registered under the Securities Act of 1933 and are being issued in reliance on a specific exemption, with the company having agreed to file a registration statement for their resale within 60 days of the closing. J.P. Morgan, Leerink Partners, TD Cowen, and Guggenheim Securities acted as the joint placement agents for the transaction. Maze Therapeutics is a company that uses human genetics to develop small molecule precision medicines, guided by its Compass™ platform, which integrates variant discovery and functionalization to advance its pipeline.

Log In
Sign Up